TrialThe Lancet. Oncology2018

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.

Jeffrey A Jones et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.